Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel + Gemcitabine + IMRT in Pancreatic Cancer
NCT02283372Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2015
- Primary completion
- May 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Primary endpoint: Maximum Tolerated Dose up to 32 months. Started Jan 2015; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02283372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283372.